Clinical trials: Limited-stage Small Cell Lung Cancer (LS-SCLC)
Limited Stage Small Cell Lung Cancer
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants.
- Trial name
- TIGOS-LS (NCT06773910)
- Testing
- BMS-986489, Durvalumab
- Where
- 34 sites in United States
- Volunteers
- 250 people
- Sponsor
- SCRI Development Innovations, LLC
Limited-stage Small Cell Lung Cancer (LS-SCLC)
Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer
The study includes the screening period (from the time the subject signs the informed consent form to no more than 28 days before the first dose, imaging evaluations are allowed within 28 days before the first dose, and 5-14 days…
- Trial name
- NCT06773156
- Testing
- Adebrelimab + Apatinib
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Small-cell Lung Cancer
The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC.
The study is being conducted to evaluate the efficacy and safety of SHR-1316 in combination with chemo-radiotherapy in patients with LS-SCLC.
- Trial name
- NCT04691063
- Testing
- SHR-1316; Carboplatin; Etoposide；Radiotherapy, Palcebo; Carboplatin; Etoposide；Radiotherapy
- Where
- China
- Volunteers
- 486 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
This phase III trial studies how well chemotherapy and radiation therapy (chemoradiation) with or without atezolizumab works in treating patients with limited stage small cell lung cancer.
- Conditions
- Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
- Trial name
- NCT03811002
- Testing
- 3-Dimensional Conformal Radiation Therapy, Atezolizumab, Biospecimen Collection
- Where
- 542 sites in United States, Japan
- Volunteers
- 544 people
- Sponsor
- National Cancer Institute (NCI)
SCLC, Limited Stage
A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy
This study aims to evaluate the efficacy and safety of adebrelimab consolidation therapy after progression-free response of concurrent chemoradiotherapy in patients with limited-stage small cell lung cancer.
- Trial name
- ARL-LS-SCLC (NCT07559786)
- Testing
- CCRT(Employed residual field irradiation(RFI)), CCRT(Involved-Field Radiotherapy (IFRT))
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Henan Cancer Hospital
Lung Cancer
Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy such as irinotecan and cisplatin use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00062322
- Testing
- cisplatin, irinotecan hydrochloride, conventional surgery
- Where
- United States
- Sponsor
- Fox Chase Cancer Center
Limited Stage Small Cell Lung Cancer
Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy
This study is a prospective, single-arm, phase II clinical trial, with 1-year PFS as the endpoint, to evaluate the efficacy and associated toxicity of Pamiparib as single-agent consolidation treatment in patients with…
- Trial name
- NCT05483543
- Testing
- Pamiparib
- Where
- 2 sites in China
- Volunteers
- 44 people
- Sponsor
- Fudan University
Myelosuppression
A Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer
The primary goal of this study is to evaluate the myelo-protective effect and safety of Trilaciclib in participants with limited stage small cell lung cancer (LS-SCLC) who are receiving concurrent chemo-radiotherapy.
- Trial name
- TRACER (NCT07881705)
- Testing
- Trilaciclib, Etoposide Injection, Carboplatin or Cisplatin Injection
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Limited-stage Small Cell Lung Cancer (LS-SCLC)
Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy
This study aims to explore the efficacy and safety of immunotherapy (PD-L1 inhibitor) maintenance following high-dose hyperfractionated simultaneous integrated boost radiotherapy concurrent chemotherapy in patients with…
- Trial name
- NCT06869239
- Testing
- Etoposide + cisplatin/carboplatin, Thoracic radiotherapy, Prophylactic cranial irradiation (PCI)
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Peking University Cancer Hospital & Institute
Small Cell Lung Cancer
SBRT Compared With IMRT Concurrently With Chemotherapy in Treating Patients With LS-SCLC
As stereotactic radiotherapy (SBRT) has been widely used in clinical practice at present, the aim of this study is to evaluate the efficacy and safety of stereotactic body radiation therapy compared with intensity modulated…
- Trial name
- NCT02738723
- Testing
- SBRT, IMRT, EP
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Third Military Medical University
Limited Stage Small-Cell Lung Cancer
Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer
Eligible participants with limited stage-small cell lung cancer (LS-SCLC) will be enrolled after completion of chemotherapy and radiation.
- Trial name
- PrE0512 (NCT07637513)
- Testing
- Tarlatamab, Durvalumab
- Volunteers
- 430 people
- Sponsor
- PrECOG, LLC.
SCLC
Accelerated Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LS-SCLC
This protocol is a phase III randomized controlled trial (RCT) evaluating the efficacy of induction chemotherapy followed by accelerated hypofractionated vs.
- Trial name
- NCT02990780
- Testing
- Conventionally fractionated concurrent chemo-radiotherapy, Accelerated hypofractionated concurrent chemo-radiotherapy
- Where
- China
- Volunteers
- 266 people
- Sponsor
- Shanghai Chest Hospital
Toripalimab, Surufatinib
Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
Based on the preclinical rationale for combining surufatinib with immunotherapy, and the clinical efficacy observed with surufatinib in extensive-stage small cell lung cancer (ES-SCLC), the investigators hypothesize that…
- Conditions
- Toripalimab, Surufatinib, Chemoradiotherapy, Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Trial name
- NCT06719700
- Testing
- Chemotherapy, Immunotherapy, Angio-immuno kinase inhibitor
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Sun Yat-sen University
Limited-stage Small-cell Lung Cancer
A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC
This study is an open-label, multicenter, phase II clinical study designed to evaluate the preliminary efficacy, safety, and tolerability of SHR-7787 in combination with Adebrelimab in patients with limited-stage small cell lung…
- Trial name
- NCT07798947
- Testing
- SHR-7787 Injection, SHR-1316
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Limited-stage Small Cell Lung Cancer (LS-SCLC)
Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung Cancer
This is a single-arm, single-center, exploratory clinical study conducted at Shanghai Pulmonary Hospital, Tongji University. The study evaluates the effectiveness and safety of first-line treatment with benmelstobart (an…
- Trial name
- Aurora004 (NCT07538258)
- Testing
- Benmelstobart, Anlotinib, Cisplatin or carboplatin
- Volunteers
- 27 people
- Sponsor
- Yayi He
Small Cell Lung Cancer Limited Stage
Durvalumab as Consolidation for Patients LS-SCLC
Small-Cell Lung Cancer (SCLC) accounts for 10% to 15% of new lung cancers and is a highly aggressive neuroendocrine tumor. In the past 30 years, the treatment of SCLC has made very limited progress, and basically made…
- Trial name
- NCT07055581
- Testing
- Induction Durvalumab +etoposide/platinum +Radiochemotherapy+ durvalumab maintenance
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Qian Chu
Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS) based on blinded independent central review (BCIR) per response evaluation criteria in solid…
- Trial name
- DeLLphi-306 (NCT06117774)
- Testing
- Tarlatamab
- Where
- 204 sites in United States, Argentina and 25 more
- Volunteers
- 404 people
- Sponsor
- Amgen
Limited-stage Small Cell Lung Cancer, LS-SCLC
A Trial of SHR-1316 Maintenance Therapy for Limited Stage Small Cell Lung Cancer
SHR-1316 as Maintenance therapy for limited stage small cell lung cancer without progression after first line platinum based concurrent chemoradiotherapy
- Trial name
- NCT04647357
- Testing
- SHR-1316
- Volunteers
- 60 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Small Cell Lung Carcinoma
Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD
This study plans to enroll limited-stage small cell lung cancer (LS-SCLC) patients who have achieved disease control after concurrent chemoradiotherapy (cCRT).
- Trial name
- NCT07357532
- Testing
- Adebrelimab Injection, Apatinib Mesylate Tablets
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Peking University Cancer Hospital & Institute
Small Cell Lung Cancer
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
Researchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung to other parts of the body.
- Trial name
- NCT04624204
- Testing
- Pembrolizumab 200 mg, Pembrolizumab 400 mg, Olaparib 300 mg BID
- Where
- 187 sites in United States, Australia and 23 more
- Volunteers
- 672 people
- Sponsor
- Merck Sharp & Dohme LLC